Results 151 to 160 of about 295,792 (196)

The SOX4-Semaphorin3C axis promotes esophageal adenocarcinoma progression. [PDF]

open access: yesCancer Lett
Fnu T   +13 more
europepmc   +1 more source

Causal relationship between GM, immune cells and esophageal adenocarcinoma: a mediation analysis based on MR. [PDF]

open access: yesJ Cardiothorac Surg
He W   +12 more
europepmc   +1 more source

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis. [PDF]

open access: yesSci Adv
Beernaert B   +31 more
europepmc   +1 more source

The role of diagnostic laparoscopy in staging distal esophageal adenocarcinoma. [PDF]

open access: yesJTCVS Open
Tsui ST   +14 more
europepmc   +1 more source

Chemotherapy for Esophageal Adenocarcinoma

open access: yes, 2018
Esophageal and esophagogastric junction adenocarcinoma is a distinct entity from esophageal squamous cell carcinoma with respect to etiology and biology despite sharing the same anatomical location. While most international treatment guidelines recommend a similar management strategy for both esophageal squamous and adenocarcinoma histologies, the ...
Ka-On, Lam, Dora L W, Kwong
openaire   +3 more sources

Epidemiology of esophageal adenocarcinoma

Journal of Surgical Oncology, 2005
AbstractThe incidence of esophageal adenocarcinoma has risen rapidly over the past 25 years in the United States as well as in several Western European countries. This increase had been most dramatic among white males. The majority of these cancers arise from a background of premalignant Barrett esophagus.
Luis Grande   +2 more
exaly   +3 more sources

Radiotherapy for Esophageal Adenocarcinoma

open access: yes, 2018
Adenocarcinomas occur in distal esophagus and often involve esophagogastric junction. Radiotherapy plays a key role in treatment, often in combination with chemotherapy and surgery in multi-modalities management. For resectable esophageal primaries, neoadjuvant chemoradiotherapy plus surgery can downstage disease and improve outcome over surgery alone.
Dora L W, Kwong, K O, Lam
openaire   +3 more sources

Target Therapy for Esophageal Adenocarcinoma

open access: yes, 2018
Adenocarcinoma of the esophagus is a deadly disease and median survival of patients with metastatic disease is around 1 year only. There is an unmet need to personalize treatment by identifying molecular targets and respective target therapy in esophageal adenocarcinoma.
Ka-On, Lam, Dora L W, Kwong
openaire   +3 more sources

Home - About - Disclaimer - Privacy